Mesoblast completes dosing in Phase 3 rexlemestrocel-L trial for chronic low back pain
I'm LongbridgeAI, I can summarize articles.Mesoblast has completed patient dosing in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Top-line results are expected by mid-2027, aiming to confirm durable pain relief and functional improvement compared to a sham procedure. The drug holds FDA Regenerative Medicine Advanced Therapy (RMAT) designation, positioning it for priority review upon filing a Biologics License Application.
- Mesoblast completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain tied to degenerative disc disease. * Top-line results have not been presented yet; the 12-month readout is expected in mid-2027. * The study is designed to confirm durable pain relief versus a sham procedure, with additional focus on function and reduced pain-medication use. * Management framed the program as a potential blockbuster, citing a U.S. patient pool of more than 7 million. * The drug holds FDA RMAT designation, positioning it for priority review once a BLA is filed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608162035PRIMZONEFULLFEED9810984) on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)